Galera Therapeutics Return on Equity

Galera Therapeutics (GRTX) currently reports a ROE of 2967.05%. That is above the Healthcare sector average of -75.84%. Use the charts on this page to explore Galera Therapeutics's ROE history and peer comparisons.

Galera Therapeutics's ROE of 2967.05% is higher than the Healthcare sector average of -75.84%. That is roughly 4012.5% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Galera Therapeutics's current 2967.05% should be judged against Healthcare norms (sector average: -75.84%) and against GRTX's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of 2967.05%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is -75.84%. From there, open related valuation or income-statement pages for Galera Therapeutics, and consider following GRTX for alerts when major investors trade the stock.

Galera Therapeutics is classified in the Healthcare sector. On ROE, it currently shows 2967.05% versus a sector average near -75.84%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing GRTX with unrelated industries.